Adherex Technologies (NASDAQ:FENC - Get Free Report) had its price objective lifted by investment analysts at HC Wainwright from $16.00 to $17.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 25.18% from the stock's current price.
Several other research analysts have also recently issued reports on FENC. Weiss Ratings upgraded shares of Adherex Technologies from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday. Zacks Research raised Adherex Technologies from a "hold" rating to a "strong-buy" rating in a report on Thursday, November 12th. B. Riley Financial restated a "buy" rating and issued a $19.00 target price (up from $18.00) on shares of Adherex Technologies in a research report on Monday. Finally, Wedbush increased their price target on Adherex Technologies from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $17.50.
Check Out Our Latest Stock Report on Adherex Technologies
Adherex Technologies Stock Performance
Shares of FENC opened at $13.58 on Wednesday. The firm has a market capitalization of $478.29 million, a price-to-earnings ratio of 182.29 and a beta of 1.29. Adherex Technologies has a one year low of $5.65 and a one year high of $13.64. The stock's fifty day moving average is $10.67 and its 200-day moving average is $9.42.
Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.02. The business had revenue of $19.61 million during the quarter, compared to the consensus estimate of $18.87 million. Adherex Technologies had a net margin of 2.52% and a return on equity of 8.96%. Analysts forecast that Adherex Technologies will post 0.32 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Robert Andrade sold 75,000 shares of the company's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total value of $883,500.00. Following the transaction, the chief financial officer owned 217,675 shares in the company, valued at $2,564,211.50. This represents a 25.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of the firm's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $12.18, for a total value of $146,160.00. Following the sale, the insider directly owned 9,519 shares of the company's stock, valued at $115,941.42. This trade represents a 55.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 10.73% of the company's stock.
Adherex Technologies Company Profile
(
Get Free Report)
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adherex Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adherex Technologies wasn't on the list.
While Adherex Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.